[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostate-obstruction-bpo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostate-obstruction-bpo":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,85,109,135,157,186,218,242,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643352","oxiblumecoq10-ralivia-therapy-for-benign-prostatic-hyperplasia-100643352",false,"NCT07638865","Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia:","Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia: a Double-blind Placebo-controlled Randomized Clinical Trial Assessing Treatment Efficacy and Safety.","Inclusion Criteria:\n\n1. Participant must be between 50 and 80 years old.\n2. Participant has signed and dated the appropriate Informed Consent document.\n3. International Prostate Symptom Score (IPSS) ≥8 and ≤30\n4. Prostate volume ≥30gram and ≤80gram\n5. Peak urinary flow rate (Qmax) ≥5 ml\u002Fsec and ≤15ml\u002Fsec\n6. Post void residual volume ≤150ml\n\nExclusion Criteria:\n\n1. Current or recurrent urinary tract infection (UTI), prostatitis, gross hematuria (blood in urine without a known cause), or a history of urinary retention.\n2. Participant has a history of prostate, bladder or urethral cancer.\n3. Participant has undergone pelvic radiation or systemic chemotherapy.\n4. Participant has undergone intravesical chemotherapy.\n5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition (except from BPH) associated with LUTS, any neurological disease or disorder affecting the bladder.\n6. Participant has undergone prostate surgery\n7. Participant with penile or urinary sphincter implants.\n8. Diagnosed neurological conditions known to affect bladder function (e.g., multiple sclerosis, Parkinson's disease, or neurogenic bladder).\n9. Significant medical conditions (e.g., unstable cardiac arrhythmias, uncontrolled diabetes, severe renal impairment) that pose an unreasonable risk to the patient or might interfere with study results.\n10. Participant has been diagnosed with cancer during the last 5 years or had any surgery in the pelvis.\n11. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.","MALE","50 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Objectives of the study\n\nThe aim of the study is to investigate and compare the treatment efficacy and safety of Oxiblume:CoQ10 (Ralivia) therapy vs placebo for BPH patients\n\nStudy center\n\nThe study will be coordinated by the research office of 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece. The research office will also support the project (logistics, quality control, management, data acquisition, publications).\n\nPatients visits will be carried out in the BPH Research Unit of the 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece.\n\nLaboratory tests of all patients will be performed at the same microbiology laboratory.\n\nStudy population A total of 100 patients (50 in Group A and 50 in Group B) with BPH diagnosis will participate in this study.\n\nStudy design Double-blind placebo-controlled randomized clinical trial\n\nZero hypothesis (H0) and alternative hypothesis (H1):\n\n(H0): Group A demonstrates similar efficacy compared to Group B for the treatment of BPH patients.\n\n(H1): Group A demonstrates greater or decreased efficacy compared to Group B for the treatment of BPH patients.\n\nStudy endpoints Primary endpoint: The difference between the Group A and Group B in the change of IPSS score from baseline to 12 weeks after treatment initiation.\n\nSecondary endpoints:\n\n* Adverse events rate in all patients during study period.\n* The difference between the Group A and Group B in the change of the IPSS score from baseline to 6 weeks after treatment initiation.\n* The difference between the Group A and Group B in the change of the following parameters from baseline to 6 and 12 weeks after treatment initiation\n\n  1. Qmax value\n  2. Prostate volume\n  3. Post void residual\n  4. IIEF-ED score\n  5. Psa value\n  6. TNFa, IL 6 values\n\nTreatment Visits :\n\nPatients accordingly to which group they will be randomized will receive:\n\n* Active treatment (Ralivia) Group : 1 pill of Ralivia per os\u002Fday for a 3-month period\n* Placebo Group : 1 placebo pill per os\u002Fday for a 3-month period\n\nAdverse events will be reported.\n\nFU Visit 1: 6 weeks after treatment initiation IPSS, IIEF-ED questionnaires will be answered. Prostate and Urinary Bladder ultrasound will be conducted pre- and post-void. Uroflowmetry will be conducted. Adverse events will be reported.\n\nPSA TNFa, IL 1β, IL 6, IL 10 will be measured through blood test.\n\nFU Visit 2: 12 weeks after treatment initiation IPSS, IIEF-ED questionnaires will be answered. Prostate and Urinary Bladder ultrasound will be conducted pre- and post-void. Uroflowmetry will be conducted. Adverse events will be reported.\n\nDRE will be performed . PSA TNFa, IL 6 will be measured through blood test.",[27,28,29],"Benign Prostate Enlargement","Benign Prostate Hypertrophy(BPH)","Benign Prostate Obstruction (BPO)","RECRUITING","2026-06-04",{"date":33,"type":34},"2026-06-10","ACTUAL",{"date":36,"type":21},"2026-06-08",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"G.Gennimatas General Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":42},"100637509","effect-of-catheter-duration-on-prostate-laser-enucleation-surgery-outcomes-in-patients-with-urinary-retention-100637509","NCT07603011","Effect of Catheter Duration on Prostate Laser Enucleation Surgery Outcomes in Patients With Urinary Retention","Evaluation of the Effect of Catheter Duration on Prostate Laser Enucleation Surgery Outcomes in Patients With Indwelling Catheters Due to Urinary Retention: A Multicenter Study of the Minimally Invasive Urology Society","Inclusion Criteria:\n\n* Patients undergoing laser enucleation of the prostate, including HoLEP, ThuLEP or ThuFLEP procedures, who have an indwelling urinary catheter due to pre-operative urinary retention.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of neurogenic bladder or prostate cancer.","18 Years",{"count":52,"type":21},54,"OBSERVATIONAL","Benign Prostatic Obstruction (BPO) is a common condition in aging men that can lead to urinary retention, often requiring the use of an indwelling urinary catheter. While laser enucleation of the prostate (such as HoLEP, ThuLEP or ThuFLEP) is a safe and effective surgical treatment, it is not well understood how the length of time a patient spent with a urethral catheter before surgery affects the final surgical outcomes. By analyzing patient data from multiple centers of the Minimally Invasive Urology Society, this study aims to evaluate the impact of preoperative catheterization duration on functional outcomes.",[56,29],"Urinary Retention",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75],"Benign Prostatic Obstruction","BPO","BPH","Benign Prostatic Hyperplasia","Bladder Outlet Obstruction","Lower Urinary Tract Symptoms","Acute Urinary Retention","Urinary Catheterization","Catheter Duration","Holmium Laser Enucleation of the Prostate","Thulium Laser Enucleation of the Prostate","HoLEP","ThuLEP","Urology","Prospective Registry","Multicenter Study","ThuFLEP","Thulium Fiber Laser Enucleation of the Prostate","2026-05-16",{"date":78,"type":34},"2026-05-22",{"date":80,"type":34},"2026-02-04",{"date":82,"type":21},"2029-02-04",{"name":84,"class":41},"Eskişehir Osmangazi University Medicine Faculty Hospital",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":42},"100640519","enucleation-ratio-as-a-novel-predictor-of-symptomatic-improvement-after-holep-100640519","NCT07591688","Enucleation Ratio as a Novel Predictor of Symptomatic Improvement After HoLEP","Predictive Value of Enucleation Ratio for Symptomatic Improvement After HoLEP: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Men aged 18 years pr older who are planned to undergo HoLEP.\n* Participants who are willing to give informed consent.\n* Participants who have moderate to severe LUTS (referring to IPSS score 8 points or more).\n* No history of previous prostate or urethral surgery.\n\nExclusion Criteria:\n\n* Unwillingness to provide informed consent.\n* Unwillingness to provide contact information or unreachability during follow-up periods.\n* Incidental diagnosis of a urogenital malignancy requiring primary treatment after enrollment (e.g., bladder tumor, renal cell carcinoma, testicular tumor).",{"count":93,"type":21},400,"The goal of this observational study is to determine whether the rate of prostate tissue removed during surgery relative to the preoperative total prostate volume (referred to as the \"enucleation ratio\") predicts symptomatic improvement 3 months after HoLEP. The main question it aims to answer is:\n\n\\- What is the minimum enucleation ratio required to achieve clinically important symptomatic improvement? (Symptomatic improvement is referred to as a threshold of having an International Prostate Symptom Score (IPSS) lower than 8 points, which is determined by the American Urological Association (AUA) and European Association of Urology(EAU)).",[29],[69,59,97,98],"LUTS","Enucleation Ratio","NOT_YET_RECRUITING","2026-05-15",{"date":102,"type":34},"2026-05-19",{"date":104,"type":21},"2026-07-01",{"date":106,"type":21},"2027-03-30",{"name":108,"class":41},"Ondokuz Mayıs University",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":53,"phases":4,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100477335","steamone---prospective-database-for-rezum-water-vapor-therapy-of-the-prostate-100477335","NCT05495633","SteamOne - Prospective Database for Rezum Water Vapor Therapy of the Prostate","SteamOne","Inclusion Criteria:\n\n* All male patients who are treated with Rezum due to prostate obstruction and LUTS in the participating study centers can be included if certain inclusion criteria are met and some exclusion criteria are not present.\n* The indication to perform Rezum needs to be made independently from the study. The decision for Rezum treatment is the responsibility of each individual practitioner and patient.\n* Age ≥ 18 years\n* Operated or supervision of surgery by a certified urologist\n* Subgroups of special interest are e.g. catheter-dependent patients, patients with oral anticoagulation, patients with preoperative urodynamic pressure-flow investigation (not older than 6 months) or patients with prostates bigger than 80 ml\n\nExclusion Criteria:\n\n* Missing informed consent\n* Lack of ability to answer questionnaires due to laguage problems or mental incapacity (e.g. in dementia, mental disability)\n* Patient does not have a personal email address available and the survey cannot be completed via a relative's email address and the patient is not willing to complete the survey on the tablet at the clinic\n* Known or suspected neurogenic bladder dysfunction in e.g. Parkinson's disease, multiple sclerosis or other neurological diseases with possible effects on bladder function\n* History of malignant bladder tumor in the last two years (including CIS) or currently present malignant bladder tumor at time of Rezum treatment (including CIS)\n* Previous operation(s) on the prostate, except prostate biopsy, if this was performed more than 4 weeks ago at time of Rezum treatment\n* Previous operation(s) on the bladder neck\n* Presence of bladder neck stenosis requiring treatment at time of Rezum treatment\n* Planned combination of Rezum treatment concurrently with another urologic (\\*) or non-urologic procedure\n\n(\\*) also the combination with a planned transurethral procedure is not allowed except for bladder stone removal",{"count":117,"type":21},1000,"60 Months","This study is to assess the clinical data of Rezum (water vapor therapy) in patients with BPO (benign prostate obstruction) and male LUTS (lower urinary tract symptoms) in terms of efficacy, durability and safety in a large, prospective, multi-center cohort consisting of 1000 \"real-life\" patients with a follow-up of 5 years.",[29],[122,123,124],"Lower Urinary Tract Symptoms (LUTS)","Rezum water vapor therapy","prostate","2026-04-30",{"date":127,"type":34},"2026-05-07",{"date":129,"type":34},"2022-12-16",{"date":131,"type":21},"2031-12",{"name":133,"class":41},"University Hospital, Basel, Switzerland",19,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100636184","outcome-and-patient-experiences-after-transurethral-resection-and-bipolar-enucleation-of-the-prostate---a-multi-center-randomized-controlled-trial-100636184","NCT07562386","Outcome and Patient Experiences After Transurethral Resection and Bipolar Enucleation of the Prostate - a Multi-center, Randomized Controlled Trial.","Inclusion Criteria:\n\nMen with prostate sizes between 30mL and 80mL on ultrasound, referred to BPH surgery, detrusor pressure ≥ 20 cmH2O on urodynamic tests, valid informed consent.\n\nExclusion Criteria:\n\nPrevious surgery for BPH, men aged above 80 years old, severe comorbidity (not suitable for surgery), cognitive impairment, prostate cancer (palliative surgery), prior pelvic radiation therapy, anticoagulation\u002Fantiplatelet therapy can't be stopped.",{"count":142,"type":21},120,[24],"In this randomized controlled trial, we will evaluate if bipolar enucleation of the prostate (BEEP) is associated with better urinary voiding outcome than transurethral resection (TURP) in men with enlarged prostate referred to surgery. In addition we will investigate the association between symptom relief and the amount of removed tissue and if patients experience differ between the two methods. Finally, we will assess cost-effectiveness of BEEP compared to TURP. The main outcome for comparison of the two surgical methods is International Prostate Symptom Score (IPSS) assessed at 12-month follow-up. The primary outcome to assess patient experience is measured with the questionnaire Nordic Patients Experience Questionnaire (NORPEQ). Cost-effectiveness will be measured with incremental cost-effectiveness ratio (ICER).",[146,29],"Lower Urinary Track Symptoms","2026-04-24",{"date":149,"type":34},"2026-05-01",{"date":151,"type":34},"2025-09-25",{"date":153,"type":21},"2028-12",{"name":155,"class":41},"Sykehuset Innlandet HF",2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":165,"minAge":50,"maxAge":4,"enrollmentInfo":166,"targetDuration":168,"studyType":53,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":183,"locationsCount":42},"100621824","the-impact-of-age-and-sex-on-anticipated-and-experienced-pain-in-first-time-outpatient-flexible-cystoscopy-100621824","NCT07375641","The Impact of Age and Sex on Anticipated and Experienced Pain in First-Time Outpatient Flexible Cystoscopy","The Effect of Age and Sex on Pre-procedural Anticipated Pain and Post-procedural Experienced Pain in Patients Undergoing Flexible Cystoscopy for the First Time in an Outpatient Setting","PAINCYST","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing flexible cystoscopy for the first time under local anesthesia in an outpatient setting\n* Ability to understand the study procedures and provide informed consent\n\nExclusion Criteria:\n\n* Use of systemic analgesics, sedatives, or anxiolytics immediately before the procedure\n* Presence of active urinary tract infection at the time of cystoscopy\n* Presence of an indwelling urethral catheter at the time of cystoscopy","ALL",{"count":167,"type":21},150,"1 Day","Cystoscopy is a procedure frequently performed in daily urological practice for the diagnosis of various urological conditions, including bladder tumors, benign prostatic hyperplasia, recurrent cystitis, and urethral strictures. Cystoscopy can be performed either in the operating room under sedation, spinal anesthesia, or general anesthesia, or in the outpatient setting under local anesthesia. Performing cystoscopy under outpatient conditions for patients requiring the procedure for follow-up and treatment indications is important in terms of reducing the workload of operating rooms. Although cystoscopy is generally well tolerated under local anesthesia in the outpatient setting, it may cause pain and anxiety in some patients, even when a flexible cystoscope is used. This may lead to adverse outcomes, particularly in patients with bladder tumors, due to loss to follow-up. Despite the use of analgesic methods such as lidocaine-based lubricants to reduce pain and anxiety before cystoscopy, an optimal solution has not yet been achieved. Moreover, some studies have reported that the level of pain experienced during cystoscopy increases with advancing age.\n\nIn male patients, several studies have demonstrated that the most painful moment during cystoscopy occurs when the tip of the cystoscope passes through the external urinary sphincter. It has been shown that asking patients to take deep breaths or allowing them to watch cystoscopy videos while manually compressing the irrigation fluid bag during the passage of the cystoscope through the bulbar urethra, just distal to the external urinary sphincter, can reduce pain perception. Female patients tend to experience less pain due to the shorter urethral length. Various strategies have been employed to minimize pain and anxiety during the procedure, including listening to music, watching relaxing videos, or allowing patients to view their own cystoscopy recordings during the examination. Given the lack of prior cystoscopy experience, we planned this randomized prospective study to evaluate the effect of age and sex on pain perception during flexible cystoscopy. We believe that the findings of this study may be beneficial in counseling patients during cystoscopic evaluation of urological pathologies",[171,172,29],"Urethral Stricture","Bladder (Urothelial, Transitional Cell) Cancer",[174,175,176],"flexible cystoscopy","outpatient urology","pain perception","2026-01-22",{"date":179,"type":34},"2026-01-29",{"date":181,"type":21},"2026-02-01",{"date":149,"type":21},{"name":184,"class":185},"Kayseri Education and Research Hospital","OTHER_GOV",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":198,"studyType":53,"phases":4,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":42},"100618677","the-effects-of-holmium-laser-enucleation-and-thulium-laser-enucleation-on-continence-urethral-stricture-and-sexual-function-in-benign-prostatic-hyperplasia-100618677","NCT07334730","The Effects of Holmium Laser Enucleation and Thulium Laser Enucleation on Continence, Urethral Stricture, and Sexual Function in Benign Prostatic Hyperplasia","A Prospective Analysis of the Effects of Holmium Laser Enucleation (HoLEP) and Thulium Laser Enucleation (ThuLEP) on Continence, Urethral Stricture, and Sexual Function in Benign Prostatic Hyperplasia","EHTCUS","Inclusion Criteria:\n\n* Diagnosis of benign prostatic hyperplasia (BPH).\n* Indication for surgical treatment of BPH.\n* Male patients aged 40-90 years.\n\nExclusion Criteria:\n\n* Patients with active urinary tract infection (UTI).\n* Patients at high risk who cannot undergo spinal or general anesthesia.\n* Patients with uncontrolled bleeding diathesis.","40 Years","90 Years",{"count":197,"type":21},200,"6 Months","This study aims to evaluate the effects of Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Laser Enucleation of the Prostate (ThuLEP), performed for the treatment of benign prostatic hyperplasia (BPH), on the following parameters: urinary continence, development of urethral or bladder neck stricture, and sexual function, including erectile function, ejaculation, and libido.",[29],[202,203,59,204,205,171,206,207,208,209],"HOLEP","THULEP","Urinary Incontinence","Sexual Function","Benign Prostate Obstruction","Benign Prostate Hyperplasia","Holmium","Thulium","2025-12-31",{"date":212,"type":34},"2026-01-12",{"date":181,"type":21},{"date":215,"type":21},"2026-10-01",{"name":217,"class":41},"TC Erciyes University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":226,"conditions":227,"keywords":232,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":4},"100597202","association-between-qmaxegfr-ratio-and-luts-severity-in-men-over-40-100597202","NCT07055425","Association Between Qmax\u002FeGFR Ratio and LUTS Severity in Men Over 40","The Role of Qmax\u002FeGFR Ratio in Assessing Symptom Severity and QoL in Men Over 40 With LUTS","Inclusion Criteria:\n\n* Male patients aged 40 years or older presenting with lower urinary tract symptoms (LUTS)\n* Able to provide informed consent\n* Willing and able to undergo uroflowmetry and blood testing\n* Able to complete the IPSS questionnaire, including the QoL item\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m²\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., prostatectomy, bladder surgery)\n* Diagnosed or suspected prostate cancer\n* Active urinary tract infection (based on clinical symptoms or urinalysis)\n* Neurological conditions affecting bladder function (e.g., Parkinson's disease, spinal cord injury)\n* Presence of an indwelling urinary catheter at enrollment\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Inability to perform uroflowmetry or complete clinical evaluations",{"count":20,"type":21},"This study will look at how well a measure called the Qmax\u002FeGFR ratio is related to the severity of urination problems in men over the age of 40. Qmax is a test that shows how fast a person can urinate, and eGFR is a number that reflects kidney function. Men who have urinary symptoms will be asked to do a urine flow test, a blood test, and fill out a questionnaire about their symptoms and quality of life. We will study if there is a link between the Qmax\u002FeGFR ratio and how severe their symptoms are. The results may help doctors better understand how kidney and urinary function are related in men with these problems.",[228,229,230,231,29],"Lower Urinary Tract Symptom","Voiding Dysfunction","Male Urological Health","Renal Function",[228,29,230,229,233],"Aging Male","2025-08-30",{"date":236,"type":34},"2025-09-05",{"date":238,"type":21},"2025-09-01",{"date":149,"type":21},{"name":241,"class":41},"Marmara University",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100596602","uroflowmetry-and-ipss-factors-influencing-surgical-decision-100596602","NCT07047599","Uroflowmetry and IPSS Factors Influencing Surgical Decision","Assessment of Clinical and Uroflowmetry Parameters as Predictors of Surgical Preference in Male Patients With Lower Urinary Tract Symptoms: A Prospective Observational Study","Inclusion Criteria:\n\n* Male patients aged 40 years and older\n* Presenting with lower urinary tract symptoms (LUTS)\n* Able to complete the IPSS questionnaire\n* Undergoing uroflowmetry as part of routine evaluation\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., TURP, HoLEP, radical prostatectomy)\n* Presence of known prostate or bladder cancer\n* Active urinary tract infection at the time of evaluation\n* Neurological conditions affecting voiding (e.g., Parkinson's disease, spinal cord injury)\n* Inability to perform uroflowmetry or incomplete IPSS data",{"count":20,"type":21},"This study aims to identify which symptoms or test findings lead men with lower urinary tract symptoms (LUTS) to consider surgical treatment. Male patients who visit the outpatient clinic for LUTS will be asked whether they would consider surgery in the future if their symptoms persist. Along with this, symptom severity scores (IPSS), quality of life scores, and uroflowmetry measurements such as maximum flow rate (Qmax) and post-void residual volume (PVR) will be collected. The goal is to determine which factors are most strongly associated with a desire for surgery. This is an observational, non-interventional study.",[228,29,229],[63,29,229,253,254],"IPSS","Urolfowmetry",{"date":236,"type":34},{"date":257,"type":21},"2025-09-15",{"date":259,"type":21},"2026-06-01",{"name":241,"class":41},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":4},"100592137","clinical-outcomes-and-ejaculatory-function-in-bpo-patients-treated-with-silodosin-100592137","NCT06989515","Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin","Does Anejaculation Reflect Better Clinical Outcomes in BPO Patients Receiving Silodosin?","Inclusion Criteria:\n\n* Male patients aged 40 years or older\n* Diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO)\n* Initiating silodosin 8 mg\u002Fday therapy for the first time\n* Able to complete IPSS and IIEF-5 questionnaires\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of prior treatment with silodosin or other α-blockers in the last 3 months\n* Known neurogenic bladder or history of neurological disease affecting voiding\n* History of prostate surgery or pelvic radiation\n* Diagnosed prostate or bladder malignancy\n* Use of medications affecting sexual function (e.g., PDE5 inhibitors) within the last month\n* Severe cardiovascular, hepatic, or renal comorbidities\n* Cognitive impairment preventing informed consent or questionnaire completion",{"count":20,"type":21},"This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.",[29,228,271,272,273],"Ejaculatory Dysfunction","Anejaculation","Silodosin",[273,271,58,63,275],"Alpha-blocker Side Effects","2025-06-04",{"date":278,"type":34},"2025-06-05",{"date":280,"type":21},"2025-06-15",{"date":282,"type":21},"2026-06-12",{"name":241,"class":41}]